Jacobs & Co. CA Has $8.36 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Jacobs & Co. CA cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,521 shares of the biopharmaceutical company’s stock after selling 161 shares during the period. Jacobs & Co. CA’s holdings in Regeneron Pharmaceuticals were worth $8,362,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of REGN. Ronald Blue Trust Inc. lifted its stake in Regeneron Pharmaceuticals by 18.8% in the third quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 12 shares during the last quarter. Rehmann Capital Advisory Group raised its stake in Regeneron Pharmaceuticals by 2.9% in the second quarter. Rehmann Capital Advisory Group now owns 463 shares of the biopharmaceutical company’s stock worth $333,000 after buying an additional 13 shares in the last quarter. Cassia Capital Partners LLC grew its stake in Regeneron Pharmaceuticals by 2.3% in the third quarter. Cassia Capital Partners LLC now owns 589 shares of the biopharmaceutical company’s stock worth $485,000 after purchasing an additional 13 shares during the period. Sutton Wealth Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares in the last quarter. Finally, Clearview Wealth Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.5% during the fourth quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock valued at $751,000 after purchasing an additional 13 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $966.30 on Thursday. The stock’s fifty day moving average is $957.54 and its two-hundred day moving average is $878.93. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $106.06 billion, a P/E ratio of 27.81, a P/E/G ratio of 2.77 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same quarter last year, the firm posted $10.96 earnings per share. The business’s revenue for the quarter was up .6% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.75 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. Barclays raised their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 6th. BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Finally, Royal Bank of Canada lifted their price objective on Regeneron Pharmaceuticals from $1,096.00 to $1,184.00 and gave the stock an “outperform” rating in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $967.59.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,707 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the transaction, the director now owns 6,382 shares of the company’s stock, valued at $6,062,900. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, Director Joseph L. Goldstein sold 2,707 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the completion of the transaction, the director now directly owns 6,382 shares of the company’s stock, valued at approximately $6,062,900. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Insiders have sold 13,729 shares of company stock worth $13,124,641 over the last three months. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.